Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Byron Donalds

Representative Byron Donalds (Republican-Florida) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on April 2nd. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/2/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 3/20/2026.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 3/20/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 3/13/2026.

Eli Lilly and Company Trading Up 3.0%

NYSE:LLY traded up $29.59 during trading hours on Tuesday, hitting $1,017.68. 3,713,172 shares of the company were exchanged, compared to its average volume of 3,191,409. The stock has a market capitalization of $958.39 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a fifty day simple moving average of $940.00 and a 200 day simple moving average of $999.39. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Daiwa Securities Group upped their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Leerink Partners lowered their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. Finally, Jefferies Financial Group set a $1,300.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly was named a top performer in pharma R&D innovation rankings, reinforcing its reputation for pipeline strength and long-term growth potential. Eli Lilly tops prominent rankings on pharma R&D performance
• Positive Sentiment: New coverage and trading activity tied to GLP-1/weight-loss policy developments may have boosted sentiment, as investors see continued demand and policy support for Lilly’s obesity drugs. Trump’s Stock Picks Perfectly Timed With New Medicare Rules: Report
• Positive Sentiment: Management confirmed progress on its KRAS pipeline after completing a key olomorasib drug-interaction study, which clarifies next steps for an important development program. Eli Lilly Completes Key Olomorasib Drug Interaction Study, Clarifying Next Steps for KRAS Pipeline
• Neutral Sentiment: Lilly also announced it will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations update with limited immediate stock impact. Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
• Negative Sentiment: The biggest overhang is the U.S. Supreme Court declining to hear Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million judgment and renewing investor concern about legal and compliance risk. US Supreme Court turns away Eli Lilly’s challenge to whistleblower law
• Negative Sentiment: Some commentary warned that Lilly’s obesity growth story is now highly valued, meaning the stock may be vulnerable if execution slips or competition intensifies. Eli Lilly Stock: Next Stop $2,000?

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently made changes to their positions in LLY. Cornerstone Wealth LLC TN bought a new position in Eli Lilly and Company in the 1st quarter valued at about $590,000. Paragon Private Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 9.5% in the first quarter. Paragon Private Wealth Management LLC now owns 2,969 shares of the company’s stock worth $2,731,000 after purchasing an additional 257 shares during the last quarter. Royal Fund Management LLC raised its stake in shares of Eli Lilly and Company by 5.8% in the first quarter. Royal Fund Management LLC now owns 4,958 shares of the company’s stock worth $4,560,000 after purchasing an additional 273 shares during the last quarter. Ariadne Wealth Management LP lifted its holdings in shares of Eli Lilly and Company by 7.1% in the first quarter. Ariadne Wealth Management LP now owns 1,234 shares of the company’s stock valued at $1,135,000 after purchasing an additional 82 shares in the last quarter. Finally, Hamilton Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 8.0% in the first quarter. Hamilton Wealth LLC now owns 1,212 shares of the company’s stock valued at $1,115,000 after purchasing an additional 90 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.